Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 6/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5396176 | 0.84 | HTR7 (0.52) | ESR2HTR7BACE1 | |
| SCHEMBL12999936 | 0.82 | ESR2 (0.58) | ESR2ALOX5TAAR1MAOBPGR | |
| SCHEMBL8593167 | 0.82 | ESR2 (0.62) | ESR2ALOX5TAAR1MAOBPGR | |
| SCHEMBL16394285 | 0.81 | TAAR1 (0.71) | ESR2ALOX5TAAR1MAOBPGR | |
| SCHEMBL31491189 | 0.81 | TAAR1 (0.71) | ESR2ALOX5TAAR1MAOBPGR | |
| SCHEMBL31222672 | 0.81 | ALOX5 (0.65) | ESR2ALOX5TAAR1MAOBPGR | |
| SCHEMBL817554 | 0.81 | ALOX5 (0.65) | ESR2ALOX5TAAR1MAOBPGR | |
| SCHEMBL3793227 | 0.80 | ESR2 (0.60) | ESR2ALOX5TAAR1MAOBPGR | |
| SCHEMBL5047034 | 0.79 | ALOX5 (0.48) | ESR2ALOX5BACE1 | |
| SCHEMBL14381971 | 0.79 | ESR2 (0.54) | ESR2ALOX5TAAR1MAOBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815226-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof | ACCRO BIOSCIENCE INC. (KY) | 2020-10-27 | — | — | US | disclosed |
| US-20190284180-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815226-B2 | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof | LITAF, BAX, TNF | ESR2 2525/4885ALOX5 84/4885TAAR1 4136/4885 |
| US-20190284180-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF | LITAF, BAX, TNF | ESR2 2525/4885ALOX5 84/4885TAAR1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.